Evaluation of Outcomes of DFine StabiliT Kyphoplasty in Vertebral Compression Fractures Due to Osteoporosis

This is a single arm, post market surveillance pilot study of an FDA cleared product, to evaluate the procedural and clinical profile of an ultra high viscosity cement vertebral augmentation system for the treatment of vertebral compression vertebral fractures due to osteoporosis.

Twenty (20) consenting evaluable adult male and female patients between the ages of 50 and 90 who meet the inclusion criteria for the study and are treated using the D-Fine StabiliT® Vertebral Augmentation System and StabiliT® Bone Cement as part of their standard treatment for osteoporotic vertebral compression fractures will be enrolled in the study.

The participants will be followed after the procedure for 3 months by telephone and/or mailed questionnaire by an IRB certified member of the research team. Information collected will include the patient's ability to ambulate independently and activity level pre and post-treatment, decrease or increase in pain level compared to pre-treatment, and monitoring adverse events. Data will be collected at enrollment, procedure, discharge (or 1 day post procedure), 1 week, 1 month and 3 months post procedure using the Visual Analog Scale (VAS) for pain score, Oswestry Disability Index. Standard of care radiographs and MRI or CT/bone scan are evaluated by a board certified radiologist. The data collected will be compared to measure outcomes.

Inclusion criteria

• Males and females 50-90 years of age
• Pain on palpation/percussion over fractured vertebral body at one to three levels that require treatment
• Compression fracture(s), T10 to L5, with bone marrow edema imaged by magnetic resonance imaging (MRI)
• Visual Analog Scale (VAS) for pain >4 on a scale of 0-10
• Oswestry score of at least a moderate disability (21-40%)
• No major surgery to the spine planned for at least 1 month following enrollment
• Life expectancy of > 6 months
• Patient has sufficient mental capacity to comply with the protocol requirements
• Availability for all study visits and phone calls
• Understands the potential risks and benefits of participating in the study and is willing to provide written informed consent.
• Vertebral compression fracture with 20-90% compression (compared to adjacent normal vertebral body)
• Fracture age < 6 months
• Signal on MRI or bone scan consistent with non-healed fracture
• Female subjects must either be no longer capable of reproduction or taking acceptable measures to prevent pregnancy during the study
• Subject must be willing and able to comply with specified follow-up evaluations

Exclusion criteria

• Primary tumors and spinal metastasis, myeloma, or lymphoma of the spine
• More than 90% compression of the vertebrae
• Level(s) above T10
• Pedicle fracture
• Neurologic deficit associated with the level(s) to be treated
• Kyphosis > 30°
• Translation > 4 mm
• Instability of posterior wall with symptomatic displacement of fragment into spinal canal or significant canal compromise
• Intercostal nerve compression
• Active systemic or local infection at the level(s) to be treated
• Myelopathy
• Uncontrolled coagulopathy
• Cannot temporarily discontinue anticoagulation therapy
• Known allergy to device materials / PMMA
• Radiculopathy
• Cord compression or canal compromise requiring surgery for decompression
• Fracture due to high energy trauma
• Severe cardiopulmonary deficiencies
• Vertebra-plana
• Disabling back pain secondary to another cause that may interfere with accurate data collection
• Subjects who are known to be pregnant (pregnancy test required within10 days of treatment or lactating
• Females capable of reproduction and will not take acceptable measures to prevent reproduction during the study
• Currently enrolled in an investigational device (IDE) that has not completed the protocol required primary follow-up period (excludes 15 year follow-up of gene therapy trials)
• Lesions involving the pedicle